Verve Therapeutics Inc. has announced a new retention bonus program for its employees, including specific retention awards for key executives. The company's Chief Financial Officer, Allison Dorval, will receive a retention award of $499,200, while Andrew Ashe, Chief Operating Officer and General Counsel, will receive $416,000. These awards are set to be paid in full on the 12-month anniversary of the Closing Date stipulated in a merger agreement, contingent upon their continued employment. In the case of termination without cause post-Closing Date, Mr. Ashe will receive the full unpaid portion immediately, while Ms. Dorval will receive 50% immediately and the remaining 50% on the Payment Date. This announcement is part of the ongoing transactions involving Verve Therapeutics, Ridgeway Acquisition Corporation, and Eli Lilly and Company, detailed in the Agreement and Plan of Merger dated June 16, 2025.